|
Study | | Treatment | Primary endpoint |
|
Platinum agents |
Alba et al. [21] | 94 | ECa followed by Db versus EC followed by D plus Cbc | pCRh |
Silver et al. [22] | 28 | Cisplatin | pCR |
Sirohi et al. [23] | 62 | Cisplatin | Clinical response rates, OSi |
Kern et al. [24] | 27 | Carboplatin plus docetaxel | pCR |
Tiley et al. [25] | 12 | ACd followed by Pe with Cb | pCR |
GeparSixto [26] | Ongoing | Carboplatin plus standard chemotherapy | pCR |
|
Targeting angiogenesis |
Ryan et al. [18] | 51 | Cisplatin plus bevacizumab | Clinical response |
CALGB 40603 [26] | Ongoing | Carboplatin and/or bevacizumab | pCR |
NCT00887575 [26] | Ongoing | Sunitinib plus pactlitaxel plus carboplatin | MTDj, pCR |
NCT01194869 [26] | Ongoing | Sorafenib plus pactlitaxel plus cisplatin | pCR |
|
Targeting DNA damage repair |
Llombart et al. [27] | 141 | Iniparib plus paclitaxel | pCR |
NCT00813956 [26] | Ongoing | Gemcitabine plus Cb plus iniparib | pCR |
I-SPY 2 [26] | Ongoing | Veliparib plus paclitaxel | pCR |
|
Targeting EGFR |
ICE [26] | Ongoing | Ixabepilone plus cetuximab | pCR |
NCT00491816 [26] | Ongoing | Erlotinib plus chemotherapy | pCR |
|
Targets HER3 |
NCT01421472 | Ongoing | Paclitaxel plus MM-121 (targets HER3) | pCR |
|
Targets inhibitors of apoptosis (IAP) |
NCT01617668 | Ongoing | Paclitaxel plus LCL161 | pCR |
|
Targets gamma-secretase/notch signaling pathway |
NCT01238133 | Ongoing | Paclitaxel plus Cb plus RO4929097 | MTD |
|
Targets PI3K/mTOR |
Gonzalez-Angulo et al. [28] | 62 | T-FECf versus TR-FECg | Clinical response rate at 12 weeks |
NCT00930930 | Ongoing | Cisplatin plus paclitaxel ± everolimus | pCR |
|
Targets multiple tyrosine kinases |
NCT00817531 | Completed | Dasatinib | Clinical response by RECIST |
|